The FDA has approved a new use for Novo Nordisk's oral semaglutide, Rybelsus, expanding its label to reduce cardiovascular risk in high-risk adults with type 2 diabetes.

#News #diabetes #type2diabetes #Obesity #FDAapproval

Sanofi presents data from a Phase II clinical trial for an investigational targeted alpha therapy, AlphaMedix , as a treatment approach for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at #ESMOef="/hashtag/ESMO25" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ESMO25.

#News #ESMO #CancerResearch #ClinicalTrial #cancer #oncology

Biotech firm I-Mab unveils global transformation, dual listing plan (US NASDAQ and Hong Kong Stock Exchange), and new focus under the NovaBridge Biosciences name.

#News #Rebrand #IPO #AMD #DME #CancerResearch

Grifols plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.

#News #USAref="/hashtag/USAmanufacturing" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#USAmanufacturing #manufacturing #onshoring #USA #Grifols #BloodTransusion

Enterome’s OncoMimics immunotherapy EO2463 gains FDA Fast Track for follicular lymphoma, paving the way for Phase III trials in in the low-tumor-burden “watch-and-wait” setting.

#News #Lymphoma #FDAfasttrack #CancerResearch #Enterome #Oncology

AbbVie's New IBD data shows endoscopic healing in Crohn's predicts long-term success. Real-world evidence for UC treatment confirms rapid symptom relief. #News #CrohnsDisease #UlcerativeColitis #IBD #EndoscopicHealing

The US FDA granted the drug Breakthrough Therapy designation to Cidara Therapeutics’ its investigational influenza prophylactic, CD388, for the prevention of influenza A and B in high-risk adults and adolescents.

#News #FluTherapy #CD388

Synchrony Medical has announced the US launch of its LibAirty Airway Clearance System, a new at-home therapy designed to assist people living with chronic lung diseases such as chronic obstructive pulmonary disease (#COPD), #bronchiectasis, and cystic fibrosis.

#News #FDAapproval

The US FDA has approved an expanded indication for Teva Pharmaceuticals' Uzedy (risperidone) extended-release injectable suspension, authorizing its use for the maintenance treatment of bipolar I disorder (BD-I) in adults.
#News #Bipolar #Schizophrenia #FDAapproval

Grifols and Biotest have launched Yimmugo in the US. The FDA-approved intravenous immunoglobulin (IVIg) provides a new treatment option for individuals with primary immunodeficiencies (PID), expanding access to critical care.

#News #Yimmugo #Immunodeficiency #PID #RareDisease #FDAapproved

Cidara Therapeutics secures up to $339M from BARDA to expand U.S. manufacturing and clinical development of CD388, its long-acting, non-vaccine influenza preventative designed to offer broad protection against all flu strains.
#News #BARDA #InfluenzaPrevention #CD388 #Biotech #PandemicPreparedness

Resitu Medical's breast biopsy device, RESL09, receives US FDA 510(k) clearance. This minimally invasive tool for large tissue samples is a breakthrough for cancer diagnostics.

#News #BreastBiopsy #FDA #MedTech #Innovation #CancerDiagnostics #Diagnostics #Breastcancer

🔬 New pooled Phase III data show Boehringer Ingelheim's nerandomilast may cut death risk in IPF & PPF by up to 59%.
#News #ERS2025 #PulmonaryFibrosis #IPF #PPF #ClinicalTrials #RespiratoryHealth

PureTech Health’s Phase IIb data show deupirfenidone (LYT-100) may stabilize lung function in #IPF patients with good tolerability—potentially a new standard of care. PureTech's Camilla Graham talks IPF landscape and drug development. #ERS2025 #PulmonaryFibrosis #ClinicalTrials #Biotech

AI adoption in MedTech is cautious but accelerating. Propel’s Chuck Serrin explains how trust, collaboration & data integrity are driving early wins in diagnostics, product ops & personalization. #MedTech
#AIinHealthcare #DigitalHealth #MedicalDevices #Innovation

Get a clinician's perspective on how AI-powered continuous glucose monitoring (CGM) is transforming diabetes care—boosting patient confidence, reducing alarm fatigue, and enabling proactive treatment.

#RealWorldData#DigitalHealth #DiabetesCare #CGM #AIinHealthcare #PatientCentricCare

Osaka is betting big on #NakanoshimaQross to turn its iPS research strength into global medical impact. With #Expo2025, Japan is showcasing its new ecosystem where academia, industry, and government converge

#News #RegenerativeMedicine #Osaka #LifeSciences #MedicalInnovation #Japan #Insight

Aphaia Pharma’s oral glucose beads improved glucose tolerance & showed strong safety in Phase 1 & 2 trials for obesity & prediabetes. Larger Phase 2 study results expected in 2026.
#News #Obesity #Prediabetes #ClinicalTrials #Biotech #Metabolism

🚨 The FDA has granted Priority Review to Chiesi's Raxone (idebenone), a potential first treatment for Leber Hereditary Optic Neuropathy (LHON), a rare disease causing sudden vision loss. Decision expected by Feb 2026.

#News #RareDisease #Ophthalmology #FDA #LHON #VisionResearch #DrugDevelopment

Affibody’s izokibep delivers positive Phase III results in hidradenitis suppurativa: 37% of patients achieved HiSCR75 at week 16 vs 20% on placebo, with strong pain and QoL improvements.

#News #EADV2025 #HS #Dermatology #ClinicalTrials #hidradenitissuppurativa

At #EASD2025, Amgen shared real-world data showing low GLP-1 adherence and highlighted MariTide, its monthly obesity therapy in late-stage trials. As next-gen treatments emerge, the focus shifts from short-term efficacy to sustainable, long-term care.

#News #Obesity #Diabetes #Pharma

Roche presented big news at #EASD2025: its Accu-Chek SmartGuide CGM now integrates with the #mySugr app after receiving CE mark approval.

#News #DiabetesCare #DigitalHealth #CGM #AI #Roche

Lipella Pharmaceuticals announces positive Phase IIa results for LP-10 in oral lichen planus, showing strong safety & efficacy. Next step: pivotal Phase IIb trial.

#News #Biotech #ClinicalTrials #OralHealth #Innovation #Pharma #Lipella

MitoRx shared new preclinical data at #EASD2025 showing its novel compound Myo4 preserves muscle and reduces liver fat in obesity models, highlighting potential beyond GLP-1 therapies.
#News #ObesityResearch #Biotech #Metabolism #DiabetesResearch

🚀 Bar-Ilan University & Sheba Medical Center launch a $120M biotech institute in Israel’s Health Tech Valley, focusing on 3D organ printing, AI in medical data, and next-gen healthcare innovation. #News #Biotech #3DPrinting #AI #HealthTech #MedicalInnovation #Israel